Mavenclad vs Generic Cladribine: Which Should MS Patients Choose in 2025?

Why This Decision Matters for MS Patients

If you’re living with relapsing multiple sclerosis and have been prescribed Mavenclad, you may be wondering: Should I switch to generic cladribine to save money?

Here’s what many MS patients don’t realize: choosing between brand Mavenclad and generic cladribine isn’t as simple as picking the cheaper option. In fact, copay assistance programs can dramatically change the cost equation. As a result, brand Mavenclad may actually cost you less out-of-pocket than generic cladribine in many cases.

Throughout this guide, we’ll answer the most common questions about generic Mavenclad. Additionally, we’ll compare effectiveness and safety, analyze costs with and without assistance programs, and help you determine which option works best for your situation.

Need help deciding between Mavenclad and generic cladribine? Call QuickRx Specialty Pharmacy at (917) 830-2525 or toll-free (800) 496-6111 for a personalized cost comparison with all assistance programs applied. You can also start your copay assistance application online.

---

What Is Cladribine and How Does It Treat MS?

Before comparing brand Mavenclad vs generic cladribine, it helps to understand what cladribine is and how it works. This section explains the basics of this MS medication.

What Is Cladribine?

Cladribine is the active ingredient in both brand-name Mavenclad and its generic version. It’s a type of medication called a purine antimetabolite. Simply put, this means it affects how certain immune cells function and grow.

According to the U.S. Food and Drug Administration (FDA), cladribine works by targeting specific white blood cells called B and T lymphocytes. These cells play a role in the abnormal immune response seen in multiple sclerosis. By temporarily lowering these cell counts, cladribine helps reduce the inflammatory attacks on the central nervous system that cause MS relapses.

What makes cladribine unique is its classification as an immune reconstitution therapy (IRT). Unlike many other MS medications that continuously suppress the immune system, cladribine works differently. It produces a targeted, temporary reduction in lymphocytes. Then, the immune system gradually recovers on its own. This approach provides lasting benefits from short treatment courses.

How Cladribine Treats Multiple Sclerosis

Both brand Mavenclad and generic cladribine treat relapsing forms of multiple sclerosis in the same way. Specifically, here’s how they help:

• First, they selectively deplete B and T lymphocytes involved in MS disease activity
• Next, they reduce inflammatory attacks on the myelin sheath protecting nerve fibers
• As a result, relapse frequency and severity decrease
• Over time, they slow disability progression
• Additionally, they reduce new brain lesion formation visible on MRI
• Finally, they provide sustained therapeutic effects lasting years after treatment courses

For more information, the National Institute of Neurological Disorders and Stroke (NINDS) provides comprehensive details about multiple sclerosis and how disease-modifying therapies like cladribine help manage this chronic condition.

---

What Is Brand Mavenclad?

Mavenclad is the brand name for cladribine tablets, made by EMD Serono. The FDA approved it on March 29, 2019. What makes Mavenclad special is that it’s the first and only short-course oral treatment for relapsing forms of MS. In other words, you only need to take pills for about 20 days over 2 years.

FDA-Approved Uses for Mavenclad

According to the FDA, Mavenclad is approved for adults with:

• Relapsing-remitting multiple sclerosis (RRMS)
• Active secondary progressive multiple sclerosis (active SPMS)

Because of its safety profile, the FDA generally recommends Mavenclad for patients who have had an inadequate response to, or are unable to tolerate, another drug indicated for the treatment of MS. Mavenclad is not recommended for patients with clinically isolated syndrome (CIS).

Mavenclad Dosing: The Short-Course Advantage

One of Mavenclad’s most distinctive features is its short-course dosing schedule. Unlike many MS medications that require daily pills, weekly injections, or monthly infusions, Mavenclad treatment involves:

• Total treatment duration: Maximum of 20 days of oral tablets over 2 years
• Year 1: Two treatment weeks (typically in months 1 and 2)
• Year 2: Two treatment weeks (typically in months 1 and 2 of year 2)
• Each treatment week: 4-5 consecutive days of tablets
• Years 3 and 4: No additional treatment needed
• Dosing: Weight-based at 3.5 mg/kg cumulative dose over 2 years

This means patients take tablets for only 8-10 days per year for two years, then typically require no further treatment for at least two additional years. According to the Mayo Clinic, this short-course approach offers a significant advantage for patients who prefer minimal treatment burden.

Mavenclad Formulation

• Form: Oral tablets
• Strength: 10 mg tablets
• Administration: Taken by mouth with water, with or without food
• Storage: Refrigerated in original packaging until use
• Special handling: Tablets should not be crushed or chewed; caregivers should use gloves when handling

---

Is Generic Cladribine Available Now?

Yes, generic cladribine tablets are now available in the United States. The FDA approved Apotex Inc.’s generic cladribine tablets 10 mg on November 24, 2025. This makes it the first generic version of Mavenclad approved for treating multiple sclerosis.

FDA-Approved Generic Cladribine Manufacturer

• Manufacturer: Apotex Inc.
• FDA approval date: November 24, 2025
• Formulation: Cladribine tablets 10 mg
• Indication: Multiple sclerosis (same as brand Mavenclad)
• Status: First-time generic approval

As a first-time generic, Apotex’s cladribine tablets have met the FDA’s rigorous bioequivalence standards, meaning they must perform identically to brand Mavenclad in the body.

Generic Cladribine Availability

Since generic cladribine was just approved in late November 2025, there are a few availability considerations to keep in mind:

• Market distribution is still ramping up at specialty pharmacies
• As a result, not all pharmacies may have generic cladribine in stock initially
• Insurance formularies may take time to add the generic option
• Supply may be limited during the initial launch period
• In the meantime, brand Mavenclad remains widely available

QuickRx Specialty Pharmacy can help you check current availability of both brand Mavenclad and generic cladribine. We’ll also identify which option is most accessible and affordable for your situation.

---

Is Generic Cladribine as Effective as Brand Mavenclad?

Yes, generic cladribine is just as effective as brand Mavenclad. The FDA requires all generic medications to be bioequivalent to the brand-name product. This means they must work the same way in your body. Both versions contain the same active ingredient (cladribine) at the same strength, so they produce the same results for multiple sclerosis.

FDA Bioequivalence Requirements

For the FDA to approve any generic medication, manufacturers must show it’s bioequivalent to the brand-name product. According to FDA generic drug standards, bioequivalence means:

• The same active ingredient (cladribine) at identical purity levels
• Identical strength (10 mg tablets)
• Matching dosage form (oral tablets)
• The same route of administration (by mouth)
• Identical performance in the body (same absorption rate and extent)
• Meeting all quality, safety, and manufacturing standards

Here’s what generic cladribine had to prove:

• Blood levels of cladribine from generic must be within 80-125% of brand levels
• Statistical analysis must confirm comparability with 90% confidence
• Same therapeutic effect expected at equivalent doses
• Identical safety profile expected

Get Inmediate Copay Assistance

917-830-2525

What Bioequivalence Means for MS Patients

When the FDA approves a generic as bioequivalent, it means the generic medication should work identically to the brand-name version. For cladribine tablets, this means you can expect:

• Equal reduction in MS relapse rates
• Identical effect on disability progression
• The same reduction in MRI lesion activity
• An identical dosing schedule (short-course over 2 years)
• Lasting therapeutic effects that match brand
• A comparable side effect profile

Clinical Evidence for Cladribine Effectiveness

The clinical evidence supporting cladribine’s effectiveness comes primarily from the CLARITY trial and follow-up studies. Here are the key findings:

• 58% reduction in annualized relapse rates compared to placebo
• Approximately 79% of cladribine-treated patients remained relapse-free over 96 weeks
• Significant reduction in sustained disability progression
• Marked reduction in new or enlarging brain lesions on MRI
• Therapeutic effects that continue for years after completing treatment courses

Because both brand Mavenclad and generic cladribine contain the same active ingredient at the same dose, these clinical benefits apply equally to both products.

---

What Are the Side Effects of Cladribine Tablets?

Brand Mavenclad and generic cladribine share the same side effects because they contain the same active ingredient. The most common side effects include lymphopenia (low white blood cell counts), upper respiratory infections, headache, and nausea. More serious side effects can include increased infection risk and potential liver problems. Because of this, your healthcare provider will monitor you closely with regular blood tests.

Common Side Effects

The most frequently reported side effects of cladribine tablets include:

• Lymphopenia (low lymphocyte counts) – expected and monitored
• Upper respiratory tract infections
• Headache
• Nasopharyngitis (common cold symptoms)
• Nausea
• Back pain
• Arthralgia (joint pain)

Serious Side Effects Requiring Medical Attention

Cladribine can cause serious side effects that require prompt medical evaluation:

Lymphopenia and Infection Risk:
This medication causes a decrease in lymphocyte counts, which is part of how it works. However, this reduction can increase susceptibility to infections, including:

• Herpes zoster (shingles)
• Serious bacterial, viral, or fungal infections
• Progressive multifocal leukoencephalopathy (PML) – rare but serious

Malignancy Risk:
Additionally, there may be an increased risk of malignancy with cladribine treatment. Your healthcare provider will discuss cancer screening recommendations.

Liver Injury:
Furthermore, cladribine can cause liver problems. Therefore, liver function tests are required before starting treatment.

Fetal Risk:
Finally, cladribine may cause harm to an unborn baby. As a result, effective contraception is required during treatment and for a specified period afterward for both male and female patients.

Required Monitoring

Before and during cladribine treatment, your healthcare provider will monitor several things:

• Complete blood counts (before, during, and after treatment)
• Lymphocyte counts, which must meet minimum thresholds before each treatment course
• Liver function tests to ensure safety
• Screening for infections including tuberculosis and hepatitis
• Varicella zoster (chickenpox/shingles) immunity status
• Pregnancy testing for women of childbearing potential
• Cancer screening as appropriate

For more details, the MedlinePlus cladribine information page provides additional information about proper use and monitoring requirements.

---

Is Generic Cladribine Cheaper Than Brand Mavenclad?

Not always. While generic medications usually have lower retail prices, your actual out-of-pocket cost depends on two things: your insurance coverage and the copay assistance programs you qualify for. Here’s the surprising part—brand Mavenclad has established manufacturer copay assistance that can significantly reduce costs for commercially insured patients. As a result, brand often ends up cheaper than generic after assistance is applied.

Why Retail Prices Don’t Tell the Full Story

Specialty medications like Mavenclad and generic cladribine have high retail prices. However, very few patients actually pay full retail cost. Here’s why:

• Most patients have insurance coverage (commercial, Medicare, or Medicaid)
• In addition, manufacturer copay assistance programs significantly reduce costs for commercially insured patients
• Furthermore, patient assistance programs help uninsured or underinsured patients
• Similarly, foundation grants assist Medicare beneficiaries

Therefore, the key question isn’t “which costs less at retail?” but rather “which costs less after all available assistance is applied?”

Insurance Coverage: Mavenclad vs Generic Cladribine

Here’s how insurance plans typically handle brand vs generic cladribine:

Formulary Tier Placement:

• Generic cladribine: Usually placed on lower specialty tier, which means lower copay before assistance
• Brand Mavenclad: Usually placed on higher specialty tier, which means higher copay before assistance

Prior Authorization:

• Both brand and generic typically require prior authorization
• However, generic may have slightly less restrictive requirements with some insurers
• Importantly, QuickRx handles prior authorization for all patients at no charge

Step Therapy:

• Some plans may require trying generic before approving brand
• Nevertheless, exceptions are available with appropriate medical documentation

The Cost Paradox: Why Brand Can Cost Less Than Generic

Here’s what surprises many MS patients: brand Mavenclad may actually cost LESS out-of-pocket than generic cladribine once copay assistance programs are factored in. Let’s explore why:

Why brand Mavenclad can cost less than generic cladribine:

• First, EMD Serono offers robust Mavenclad copay assistance programs with substantial annual benefits
• Second, brand manufacturer copay cards can reduce patient costs to minimal amounts monthly
• By contrast, generic cladribine manufacturers typically have more limited patient assistance resources
• As a result, generic copay assistance, when available, often provides smaller benefit amounts
• Consequently, insurance prefers generics (lower tier), but patient final costs can paradoxically be higher without robust assistance

Real-world cost example:

Consider an MS patient with standard commercial insurance:

• First, brand Mavenclad copay before assistance: Higher amount
• Then, brand Mavenclad copay after manufacturer card: Significantly reduced
• Meanwhile, generic cladribine copay before assistance: Lower amount
• However, generic cladribine copay with limited assistance: May remain higher than brand after assistance

Consequently, personalized cost analysis is essential—you cannot know which option costs less until copay assistance programs are properly applied to your specific situation.

---

What Copay Assistance Is Available for Mavenclad vs Generic Cladribine?

Brand Mavenclad currently has more copay assistance options than generic cladribine. EMD Serono offers established copay cards for commercially insured patients, plus patient assistance programs for uninsured patients. On the other hand, generic cladribine assistance programs are still developing since the generic was just approved in November 2025. For Medicare patients, foundation grants work equally well for either brand or generic.

Brand Mavenclad Copay Assistance Programs

EMD Serono Copay Assistance for Mavenclad (Commercially Insured Patients):

• Reduces Mavenclad out-of-pocket costs significantly
• Available for patients with commercial insurance coverage
• Simple enrollment process (QuickRx handles enrollment free of charge)
• Annual benefit renewals available

Who qualifies for Mavenclad copay assistance:

• MS patients with commercial insurance (employer-sponsored or private plans)
• Valid Mavenclad prescription from licensed healthcare provider
• NOT available for Medicare, Medicaid, VA, TRICARE, or other government insurance

Mavenclad Patient Assistance Program (Uninsured Patients):

• May provide free medication for qualifying uninsured or underinsured patients
• Eligibility based on financial need
• Requires application with documentation
• QuickRx assists with applications at no charge

Foundation Grants for Mavenclad (Medicare Patients):

• Independent foundations offer grants for MS patients on Medicare
• Grants help cover Part D copays, coinsurance, and deductibles
• Funding varies by foundation and availability
• QuickRx monitors foundation openings and assists with applications

Generic Cladribine Copay Assistance Programs

Because generic cladribine was just approved in November 2025, assistance programs are still developing. Here’s what we know so far:

• Currently, generic manufacturers typically offer more limited copay assistance compared to brand
• As a result, assistance program availability and benefit amounts may vary
• Over time, programs may expand as generic enters the market
• However, foundation grants (for Medicare) already apply to both brand and generic equally

Copay Assistance Comparison Summary

Assistance Type	Brand Mavenclad	Generic Cladribine
Copay Cards (Commercial Insurance)	Established program with substantial benefits	Limited or developing programs
Foundation Grants (Medicare)	Same foundations cover both	Same foundations cover both
Patient Assistance (Uninsured)	Established manufacturer program	Limited or developing programs
Specialty Pharmacy Support	Extensive enrollment support	Less manufacturer infrastructure

Key takeaway: Copay assistance is currently more robust and established for brand Mavenclad. As generic cladribine market presence grows, assistance programs may expand. QuickRx monitors all available programs and helps patients access maximum savings regardless of which product they choose.

---

Should I Choose Brand Mavenclad or Generic Cladribine?

It depends on your insurance type. Commercially insured patients often pay less for brand Mavenclad when manufacturer copay assistance is applied. In contrast, Medicare patients may save more with generic cladribine since they can’t use manufacturer copay cards. Meanwhile, uninsured patients typically have better access to established brand patient assistance programs. The only way to know for certain is to compare actual costs with all assistance applied to your specific situation.

When Brand Mavenclad May Be the Better Choice

Brand Mavenclad may cost less or be more accessible in these situations:

• Commercial insurance with eligibility for manufacturer copay assistance
• Copay card benefits that bring your costs below generic pricing
• Preference for an established product with extensive patient support resources
• Insurance prior authorization that’s easier to obtain for brand
• Limited generic cladribine availability at your preferred pharmacy

When Generic Cladribine May Be the Better Choice

On the other hand, generic cladribine may cost less if:

• Medicare Part D coverage (since you cannot use manufacturer copay cards)
• Foundation grants that cover a larger percentage of lower generic costs
• Insurance that strongly prefers generics with better tier placement
• Uninsured status where generic pricing is more accessible
• Insurance requiring generic first before covering brand

For Medicare Patients

Medicare beneficiaries cannot use manufacturer copay cards due to federal regulations. However, there are still ways to save. Here’s what Medicare patients should know:

• Independent foundation grants apply equally to brand and generic
• Because generic has a lower baseline cost, grants may cover more of your expense
• QuickRx helps identify all available foundation programs
• Additionally, we assist with Medicare Part D plan optimization during annual enrollment

Need Mavenclad Copay Assistance?

Start Your Application

For Commercially Insured Patients

Patients with employer or private insurance have the most options. As a result, you can often find significant savings. Here’s what to consider:

• Manufacturer copay cards are available (brand only)
• You can compare final costs with all assistance applied
• QuickRx calculates exact out-of-pocket costs for both options
• Then we recommend whichever option provides the greatest savings

For Uninsured Patients

Patients without insurance coverage still have options. Here’s what’s available:

• Brand Mavenclad has established patient assistance programs
• Generic assistance programs are still developing
• QuickRx explores all options to find affordable access
• If eligible, we can also assist with insurance enrollment

---

Frequently Asked Questions: Mavenclad vs Generic Cladribine

Is generic Mavenclad available now?

Yes, generic cladribine tablets were approved by the FDA on November 24, 2025. Apotex Inc. received approval for cladribine tablets 10 mg, making this the first generic version of Mavenclad in the United States. Since this is a very recent approval, availability at pharmacies may still be ramping up. QuickRx can help you check current availability of both brand and generic options.

Is generic cladribine as effective as brand Mavenclad?

Absolutely. Generic cladribine must meet FDA bioequivalence standards, which means it performs identically to brand Mavenclad in the body. Both versions contain the same active ingredient at the same strength (10 mg tablets). Therefore, they produce the same therapeutic effects for multiple sclerosis.

Will generic cladribine be cheaper than Mavenclad?

Not necessarily. While generic medications usually have lower retail prices, your actual out-of-pocket cost depends on insurance coverage and available copay assistance programs. Brand Mavenclad has established copay assistance that can significantly reduce costs for commercially insured patients. In fact, many patients pay less for brand Mavenclad with copay assistance than they would for generic cladribine. QuickRx provides personalized cost comparisons to help you find the most affordable option.

Can Medicare patients get copay assistance for cladribine?

Medicare patients cannot use manufacturer copay cards due to federal anti-kickback regulations. However, independent charitable foundations offer grants specifically for MS patients on Medicare. These foundation grants apply equally to both brand Mavenclad and generic cladribine. As a result, they can help cover Part D copays, coinsurance, and deductibles. QuickRx specializes in helping Medicare patients access these grants.

Can I switch between brand Mavenclad and generic cladribine?

Yes, you can switch between brand and generic cladribine with your neurologist’s approval. Since both contain identical active ingredients at the same dose, switching should not affect treatment effectiveness. Just make sure your healthcare provider is informed of any changes. If you’re mid-treatment course, discuss timing of any switch with your doctor first.

What if my insurance requires generic cladribine?

Many insurance plans implement generic-first policies that require trying generic medications before covering brand alternatives. If your insurance requires generic cladribine, QuickRx can help you understand your options. For example, brand Mavenclad might actually cost less with copay assistance even if insurance prefers generic. We can also assist with exception requests if there’s a medical reason you need brand Mavenclad specifically.

How does QuickRx help with Mavenclad and generic cladribine?

QuickRx Specialty Pharmacy provides complete support for MS patients taking cladribine tablets. Our services include:

• Personalized cost analysis comparing brand vs generic with all assistance applied
• Free copay assistance enrollment for all available programs
• Prior authorization handling and insurance coordination
• Foundation grant applications for Medicare patients
• Medication delivery and ongoing support
• Annual renewal management for assistance programs

We help you access the most affordable option—whether that’s brand Mavenclad or generic cladribine—based on your specific situation. Call (917) 830-2525 or (800) 496-6111 to get started.

What are the side effects of cladribine tablets?

Both brand Mavenclad and generic cladribine share the same side effect profile because they contain identical active ingredients. Common side effects include lymphopenia (low lymphocyte counts), upper respiratory infections, headache, and nausea. More serious side effects can include increased infection risk, potential malignancy risk, and liver problems. Because of these risks, your healthcare provider will monitor you closely with blood tests before, during, and after treatment. Be sure to report any concerning symptoms to your doctor promptly.

---

How Do I Find Out Which Option Costs Less for Me?

Contact QuickRx Specialty Pharmacy for a free, personalized cost comparison. We’ll check your insurance coverage, apply all available copay assistance programs to both brand Mavenclad and generic cladribine, and show you the exact out-of-pocket cost for each option. Call (917) 830-2525 or (800) 496-6111 for immediate help.

Three Ways to Get Started

1. Call QuickRx for Immediate Cost Analysis 📞
(917) 830-2525 | (800) 496-6111
We’ll analyze your insurance coverage and show you exact costs for both Mavenclad and generic cladribine with all assistance programs applied.

2. Apply Online for Copay Assistance
Complete our copay assistance application →
We’ll calculate costs for both brand and generic options and provide a clear recommendation.

3. Visit Our Mavenclad Copay Assistance Page
Learn more about Mavenclad copay assistance →

What Happens After You Contact QuickRx?

Within 24 Hours:

• Insurance coverage verified for both brand Mavenclad and generic cladribine
• All available copay assistance programs identified
• True out-of-pocket costs calculated with assistance applied
• Clear recommendation provided on which option costs less

Within 1-2 Weeks:

• Copay assistance programs activated
• Prior authorization obtained
• Your prescribed medication processed at lowest available cost
• Medication delivered with necessary supplies and information

Why MS Patients Trust QuickRx

• Specialty pharmacy expertise with MS medications including Mavenclad
• Complete cost analysis with all manufacturer and foundation programs applied
• Insurance navigation including prior authorizations and appeals
• Free copay assistance enrollment—we never charge for this service
• Ongoing cost optimization as programs and coverage change
• Compassionate support from a team that understands MS challenges

---

What’s the Bottom Line on Brand vs Generic Mavenclad?

Both brand Mavenclad and generic cladribine work equally well for treating MS—the real difference is cost. Don’t assume generic is cheaper. With copay assistance programs factored in, brand Mavenclad often costs less than generic for commercially insured patients. That’s why you should let QuickRx run the numbers for your specific situation before you decide.

Here’s a quick summary by insurance type:

For most commercially insured patients: Brand Mavenclad with manufacturer copay assistance often costs less than generic cladribine.

For most Medicare patients: In contrast, generic cladribine may provide greater savings with foundation grants applied, though both options work equally well clinically.

For uninsured patients: Currently, brand Mavenclad has more established patient assistance programs, though options continue to evolve.

For all patients: Regardless of insurance type, QuickRx calculates your exact personalized costs with all assistance applied and recommends the most affordable choice.

In conclusion, don’t make this decision based on assumptions. Instead, get accurate information, then choose confidently.

Call QuickRx today at (917) 830-2525 or (800) 496-6111 and let our specialty pharmacy experts show you which option—brand Mavenclad or generic cladribine—truly costs less for your specific situation.

---

Medical References & Sources

1. U.S. Food and Drug Administration (FDA). Mavenclad (cladribine) Prescribing Information. Available at: https://www.fda.gov/. Accessed December 2025.
2. U.S. Food and Drug Administration (FDA). Generic Drug Facts. Available at: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts. Accessed December 2025.
3. Drugs.com. Generic Drug Approvals – November 2025. Cladribine Tablets 10 mg (Apotex Inc.) Approved November 24, 2025. Available at: https://www.drugs.com/. Accessed December 2025.
4. National Institute of Neurological Disorders and Stroke (NINDS). Multiple Sclerosis Information. Available at: https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis. Accessed December 2025.
5. Mayo Clinic. Multiple Sclerosis – Symptoms and Causes. Available at: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269. Accessed December 2025.
6. MedlinePlus. Cladribine Drug Information. Available at: https://medlineplus.gov/druginfo/meds/a619025.html. Accessed December 2025.
7. Cleveland Clinic. Oral Cladribine (Mavenclad) for MS – Mellen Center Approach. Available at: https://my.clevelandclinic.org/. Accessed December 2025.
8. National Multiple Sclerosis Society. Disease-Modifying Therapies for MS. Available at: https://www.nationalmssociety.org/. Accessed December 2025.
9. Giovannoni G, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis (CLARITY). N Engl J Med. 2010;362(5):416-426.
10. EMD Serono. Mavenclad FDA Approval Press Release. March 29, 2019.

---

Disclaimer: This article provides general information about Mavenclad (cladribine) and generic cladribine and is intended for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with questions about your medical condition or treatment. QuickRx Specialty Pharmacy does not provide medical advice or treatment recommendations. Information about copay assistance programs is subject to change; eligibility and benefits vary by program and individual circumstances.

Last Updated: December 2025
Reviewed By: QuickRx Clinical Team